Intellipharmaceutics Financial Statements From 2010 to 2024

Intellipharmaceutics financial statements provide useful quarterly and yearly information to potential Intellipharmaceutics International investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Intellipharmaceutics financial statements helps investors assess Intellipharmaceutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Intellipharmaceutics' valuation are summarized below:
Intellipharmaceutics International does not presently have any fundamental trends for analysis.
Check Intellipharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intellipharmaceutics main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Intellipharmaceutics financial statements analysis is a perfect complement when working with Intellipharmaceutics Valuation or Volatility modules.
  
This module can also supplement various Intellipharmaceutics Technical models . Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.

Intellipharmaceutics EBITDA Analysis

Intellipharmaceutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Intellipharmaceutics EBITDA

    
  (12.73 M)  
Most of Intellipharmaceutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Intellipharmaceutics International reported earnings before interest,tax, depreciation and amortization of (12.73 Million). This is 101.45% lower than that of the Healthcare sector and 112.71% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.33% higher than that of the company.

Intellipharmaceutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Intellipharmaceutics's current stock value. Our valuation model uses many indicators to compare Intellipharmaceutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intellipharmaceutics competition to find correlations between indicators driving Intellipharmaceutics's intrinsic value. More Info.
Intellipharmaceutics International is currently regarded as number one stock in beta category among related companies. It is currently regarded as number one stock in shares owned by institutions category among related companies producing about  4.00  of Shares Owned By Institutions per Beta. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Intellipharmaceutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Intellipharmaceutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intellipharmaceutics' earnings, one of the primary drivers of an investment's value.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Intellipharmaceutics information on this page should be used as a complementary analysis to other Intellipharmaceutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Intellipharmaceutics Stock

If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope